Patents for A61P 19 - Drugs for skeletal disorders (81,981)
01/2004
01/15/2004WO2004005293A2 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
01/15/2004WO2004005265A1 Quinazoline derivatives
01/15/2004WO2004005258A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors
01/15/2004WO2004004781A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL
01/15/2004WO2004004780A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
01/15/2004WO2004004779A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine
01/15/2004WO2004004778A1 Use of cetp inhibitors and optionally hmg coa reductable inhibitors and/or antihypertensive agents
01/15/2004WO2004004776A1 Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
01/15/2004WO2004004770A1 Chemotactic factor inhibitor for modulating inflammatory reactions
01/15/2004WO2004004750A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
01/15/2004WO2004004736A1 Novel use of imidazotriazinones
01/15/2004WO2004004722A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
01/15/2004WO2004004720A1 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
01/15/2004WO2004004665A2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
01/15/2004WO2004004663A2 Compositions and methods for ligament growth and repair
01/15/2004WO2004004633A2 Use of tnfalpha antibodies and another drug
01/15/2004WO2004004482A1 Milk protein isolate and method for preparing same
01/15/2004WO2003092608A3 Methionine aminopeptidase-2 inhibitors and methods of use thereof
01/15/2004WO2003091247A3 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
01/15/2004WO2003089434A3 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF
01/15/2004WO2003084936A8 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
01/15/2004WO2003080118A3 Combination of an aldosterone receptor antagonist and a fibric acid derivative
01/15/2004WO2003079969A3 Compositions and methods for treating and preventing necrosis
01/15/2004WO2003062191A8 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
01/15/2004WO2003019146A3 High throughput screening assays using fatty acid synthetic enzymes
01/15/2004WO2002096866A3 Thiolalkyl benzoic acid derivatives
01/15/2004WO2002080888A3 Estrogen receptor-related receptor alpha (err) agonist for inducing cartilage formation
01/15/2004WO2002046364A8 Genes associated with mechanical stress, expression products therefrom, and uses thereof
01/15/2004US20040010148 Antiinflammatory agents, antiallergens, antiproliferative agents, immunosuppressants, antidiabetic agents, cardiovascular disorders
01/15/2004US20040010141 Antiinflammatory agents; anticancer agents; rheumatic disorders; cardiovascular disorders
01/15/2004US20040010134 Albumin fusion proteins
01/15/2004US20040010027 Tumor angiogenesis and metastasis inhibition.
01/15/2004US20040010023 Biphenyl derivatives and the use thereof as integrin inhibitors
01/15/2004US20040010020 Trifluoromethyl-substituted nitrogen compounds; treating type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma
01/15/2004US20040010019 Aromatic sulfone hydroxamates and their use as protease inhibitors
01/15/2004US20040010013 Cannabinoid receptor ligands
01/15/2004US20040010010 Melanocortin receptor ligands
01/15/2004US20040010008 Piperidine derivatives useful as CCR5 antagonists
01/15/2004US20040009998 Spiro-hydantoin compounds useful as anti-inflammatory agents
01/15/2004US20040009996 4-(1,2- or 2,1-benzoxazol-5-yl)-2-aminopyrimidines
01/15/2004US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade
01/15/2004US20040009984 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure
01/15/2004US20040009983 Azaindoles
01/15/2004US20040009981 Oxazole, thiazole, 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives of pyrimidines, 1,2,4- and 1,3,5-triazines
01/15/2004US20040009980 Calcilytic compounds
01/15/2004US20040009974 Pyrimidylamino- or triazinylamino- substituted pyrazoles or 1,2,3-triazoles
01/15/2004US20040009968 Indazole compounds useful as protein kinase inhibitors
01/15/2004US20040009966 Interleukin converting enzyme inhibitors
01/15/2004US20040009950 Secreted human proteins
01/15/2004US20040009914 Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
01/15/2004US20040009901 Identifying and administering an agent that enhances NADPH oxidase activity; diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency
01/15/2004US20040009895 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin
01/15/2004US20040009505 A pair of genetic engineered primers for the mutagenic amplification, therapeutic treatment
01/15/2004US20040009244 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
01/15/2004US20040009233 Shark meat extract
01/15/2004US20040009231 hGH (human growth hormone) formulations for pulmonary administration
01/15/2004US20040009228 Bioabsorbable drug delivery system for local treatment and prevention of infections
01/15/2004US20040009167 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism
01/15/2004US20040009163 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
01/15/2004DE10227938A1 Pharmazeutische Zubereitung, Verfahren zu ihrer Herstellung sowie deren Verwendung A pharmaceutical preparation, processes for their preparation and their use
01/15/2004DE10226326A1 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene 9-alpha-substiuierte estratrienes as selective estrogens effective
01/15/2004CA2492122A1 Novel tricyclic spiropiperidines or spiropyrrolidines
01/15/2004CA2491848A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
01/15/2004CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol
01/15/2004CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine
01/15/2004CA2491513A1 Compositions and methods for ligament growth and repair
01/15/2004CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
01/15/2004CA2491455A1 Novel use of imidazotriazinones
01/15/2004CA2491132A1 Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
01/15/2004CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
01/15/2004CA2490708A1 Mutant fab fragments of the chimeric 13b8.2 anti-cd4 antibody and uses thereof
01/15/2004CA2490463A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
01/15/2004CA2490097A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors
01/15/2004CA2489860A1 Use of an antibody against s100a8 or s100a9 as chemotactic factor inhibitor for modulating inflammatory reactions
01/15/2004CA2489402A1 New compounds, compositions and methods for treatment of inflammatory diseases and conditions
01/15/2004CA2489398A1 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
01/15/2004CA2489251A1 Quinazoline derivatives
01/15/2004CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents
01/14/2004EP1380579A1 Novel physiologically active substances
01/14/2004EP1380562A1 Carboxylic acid derivative and salt thereof
01/14/2004EP1380296A1 Hsp inductor
01/14/2004EP1380293A1 Bone metabolism improving agents
01/14/2004EP1379695A2 New polynucleotides and polypeptides of the ifnalpha-21 gene
01/14/2004EP1379694A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
01/14/2004EP1379679A2 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof
01/14/2004EP1379628A2 Kinases and phosphatases sequences, and use thereof
01/14/2004EP1379542A2 Treatment of tumours
01/14/2004EP1379533A2 Novel cyclo azaphospha hydrocarbons
01/14/2004EP1379528A1 Pyrazolopyrimidines as therapeutic agents
01/14/2004EP1379524A2 Chromane derivatives, process for their preparation and their use as antitumor agents
01/14/2004EP1379519A1 Pyrrolidine sulfonamides
01/14/2004EP1379508A2 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
01/14/2004EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
01/14/2004EP1379504A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
01/14/2004EP1379495A2 Ligands of the alpha-v-beta 6 integrin
01/14/2004EP1379494A1 Fused bicyclic or tricyclic amino acids
01/14/2004EP1379282A2 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
01/14/2004EP1379276A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
01/14/2004EP1379268A1 Chondrogenic potential of human bone marrow-derived cd105?+ cells by bmp
01/14/2004EP1379257A2 Prodrugs of anticancer agents employing substituted aromatic acids